A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Study Summary

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.

Conditions

Myelofibrosis

Interventions / Drugs

Imetelstat Best Available Therapy (BAT)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment327 participants

Primary Completion—

Lead SponsorGeron Corporation

Data Retrieved2026-04-11 04:14:35.168063+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.